Charles Schwab Investment Management Inc Cogent Biosciences, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 825,793 shares of COGT stock, worth $7.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
825,793
Previous 686,697
20.26%
Holding current value
$7.69 Million
Previous $5.79 Million
54.08%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
114MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$97.5 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$86 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$70.2 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$67.9 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$64.8 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $612M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...